What is HYPR's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for HYPR.

Stock Ratings / Health Care / HYPR / options

OM (34) ECOR (29) STXS (22) NRXS (36) ⌘ Pro Terminal →

Hyperfine Inc. (Class A) (HYPR) Options Positioning, Max Pain & Unusual Sweeps

$0.72 +0.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.72

Hyperfine Inc. (Class A) (HYPR) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $76.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HYPR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HYPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Hyperfine Inc. (Class A) (NASDAQ: HYPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.72 (+0.99% 1D, market cap $76.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, HYPR ranks #511 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HYPR compare to OM and ECOR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), HYPR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 49.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M) and ECOR (electroCore Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M). Among the 5-stock peer group, HYPR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HYPR?

▼

Per HYPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833769), Hyperfine Inc. (Class A) generated $13.6M in revenue (+5.2% YoY), -$35.6M in net income, and -$29.1M in free cash flow against $55.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.72 (-0.01%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HYPR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY HYPR SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 49.8% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.85-9.4% Next Q

Q2 (-2Q)

Grade D$0.77-2.6% Next Q

Q3 (-1Q)

Grade D$0.75-4% Next Q

Current

Grade D-$0.72-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HYPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HYPR currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.81) and Max Pain ($0.76) forces dealer call-delta covering toward $2.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HYPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HYPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HYPR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HYPR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HYPR)

✓Walkthrough of HYPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HYPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -60.22%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.75H $0.75L $0.72C $0.72VOL 565.6K

RES: $1.05SUP: $0.64SMA50: $0.81SMA200: $1.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HYPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HYPR Butterfly Map → + Track HYPR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HYPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HYPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HYPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HYPR)

Health Care Rank #511 of 1015 ⚔️ OM vs HYPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HYPR vs. OM, ECOR, STXS, NRXS)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Hyperfine Inc. (Class A) (HYPR) ranks #511 by composite RQD confidence (38/100, grade D-) and #686 by equity capitalization ($76.1M). Within this direct 5-issuer industry benchmark cohort, HYPR leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HYPR ACTIVE Hyperfine Inc. (Class A)	D-	38/100	—	49.8%	-35.0%	+0.99%	$76.1M	Benchmark Subject
OM Outset Medical Inc.	E	34/100	—	39.1%	-28.0%	-0.25%	$75.8M	/om-vs-hypr →
ECOR electroCore Inc.	E	29/100	—	86.8%	-35.0%	-4.79%	$67.8M	/ecor-vs-hypr →
STXS Stereotaxis Inc.	E	22/100	—	52.7%	-35.0%	+2.03%	$86.4M	/stxs-vs-hypr →
NRXS Neuraxis Inc.	D-	36/100	—	84.2%	-35.0%	-7.43%	$89.5M	/nrxs-vs-hypr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001833769 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hyperfine Inc. (Class A) (HYPR) reported GAAP revenue of $13.6M (+5.2% vs. FY2024 revenue of $12.9M , and +22.9% cumulative change since FY2023) , GAAP net income of -$35.6M, operating cash flow of -$27.9M, and free cash flow of -$29.1M (+25.6% YoY). On the balance sheet, HYPR closed FY2025 with $55.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$13.6M	-$35.6M	-$27.9M	-$29.1M	$55.3M	$0
FY2024 (FY)	2024-12-31	$12.9M	-$40.7M	-$38.8M	-$39.1M	$58.9M	—
FY2023 (FY)	2023-12-31	$11.0M	-$44.2M	-$41.8M	-$41.8M	—	—

3. HYPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HYPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HYPR compare to OM and ECOR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HYPR?

Where is HYPR trading relative to its 50-day, 200-day, and 52-week technical levels?

HYPR last traded at $0.72 (+0.99% on volume of 198,665 shares), positioning the stock -11.11% below its 50-day simple moving average ($0.81) and -36.28% below its 200-day simple moving average ($1.13). Across its 52-week range of $0.70 to $1.93, HYPR sits at the 1.6% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).

Direct Sub-Reports: HYPR RQD Cockpit HYPR 12M Forecast HYPR Earnings & Move HYPR Dividends & DRIP HYPR Insiders & 13F HYPR Whale Options HYPR Profit Sankey HYPR News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

HYPR — Hyperfine Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Hyperfine Inc. (Class A) (HYPR) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.72 (+0.99% 1D, market capitalization $76.1M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 49.8%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (6/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Hyperfine Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Hyperfine Inc. (Class A) (HYPR) reported $13.6M in annual revenue (up from $12.9M in FY2024, +5.2% YoY) and -$35.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($11.0M revenue, -$44.2M net income) through FY2025, HYPR scaled operating cash flow to -$27.9M and free cash flow to -$29.1M, backed by $55.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.70 – $1.93 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists supply_chain as "NONE," with no upstream or downstream links and no sector-correlation signals. The source data therefore does not identify specific upstream suppliers, downstream customers, or second-order bottlenecks.

Key Question #1: Can HYPR sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $13.6M and free cash flow of -$29.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is HYPR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HYPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Hyperfine Inc. (Class A) (HYPR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HYPR Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 22h ago

Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% Sequentially

Yahoo Finance report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Hyperfine Stock Price Forecast. Should You Buy HYPR?

StockInvest.us report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Hyperfine, Inc. Estimates – NASDAQ:HYPR

TradingView report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Full Transcript: Hyperfine Q2 2026 Earnings Call

Benzinga report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

Hyperfine Reports Preliminary Q3 Revenue of Approximately $6.0 Million | HYPR Stock News

Quiver Quantitative report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Six German symphony performances bring brain scans onstage

Stock Titan report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Hyperfine (HYPR) Holds Near $0.72 as Traders Eye $0.68 Support - Inverse ETF Flow

https://www.siam.in/ report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HYPR Bull vs. Bear Conversation Board — What's Your Call at $0.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HYPR 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $0.84 (+16.7%)

📌 Pinned Debate

Revenue grew from $11.0M in FY 2023 to $13.6M in FY 2025 while the balance sheet carried $35.1M of cash against $0.0M of reported debt.

The street is overcomplicating Hyperfine Inc. (Class A) (HYPR). Revenue grew from $11.0M in FY 2023 to $13.6M in FY 2025 while the balance sheet carried $35.1M of cash against $0.0M of reported debt.. With an RQD score of 38/100 (D-) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.78.

VolSurface_Trader 🐂 BULL

Both sides have a point here — HYPR's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.59 (-18.1%)

Spot @ $0.72

Operating margin of -60% and FCF of -$29.1M in FY 2025 leave the company without a self-funding cash engine and a 0% FCF yield.

Operating margin of -60% and FCF of -$29.1M in FY 2025 leave the company without a self-funding cash engine and a 0% FCF yield.. Look at the math on HYPR: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Electromedical & Electrotherapeutic Apparatus demand softens. I'd wait for a retest of $0.63 before getting long.